Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025 Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2 filings.

Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025: Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2… 👈 Read full analysis #PumaBiotechnology #Nerlynx #Q42025 #Pharmaceuticals #BiotechInvesting

Frontiers | Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 block...

www.frontiersin.org/journals/onc...

#Cancer #Kanser #BreastCancer #MemeKanseri #MedSky #OncSky #bcsm #enhertu #nerlynx #faslodex #taxol

New Breast Cancer Treatment Offers Hope for HER2-Positive Women in Thailand A groundbreaking therapy, NERLYNX®, has been approved for breast cancer treatment in Thailand, promising better outcomes for HER2-positive patients. This marks a significant milestone in cancer care.

New Breast Cancer Treatment Offers Hope for HER2-Positive Women in Thailand #Thailand #Bangkok #NERLYNX #HER2+

HER2扩增转移性乳腺癌德曲妥珠单抗治疗复发获益奈拉替尼|单抗|患者|联合|拷贝数|乳腺癌|-健康界 本研究首次报道HER2-TKI联合方案在T-DXd耐药转移性乳腺癌中的显著疗效。

Neratinib-based treatment in post-T-DXd setting.

#breastcancer #memekanseri #enhertu #nerlynx

www.cn-healthcare.com/articlewm/20...

New Breast Cancer Treatment Approved in Thailand Heralds Hope for Patients Reducing Recurrence Risks A new breast cancer therapy, NERLYNX, has received approval in Thailand, showing promise in reducing recurrence risks and improving patient survival rates.

New Breast Cancer Treatment Approved in Thailand Heralds Hope for Patients Reducing Recurrence Risks #Breast_Cancer #N/A #Thailand #NERLYNX